In the latest episode of The Wills Retina Report, Regillo and Ho discuss where gene therapy stands for retinal disease, from late-stage programs in neovascular age-related macular degeneration to earlier efforts in geographic atrophy and diabetic retinopathy.
LUGANO missed its visual noninferiority endpoint for the vorolanib insert vs aflibercept in nAMD despite comparable anatomic control. Regillo attributes the gap partly to 9 outliers with vision loss unrelated to nAMD.
In the latest episode of The Wills Retina Report, Dr. Regillo and Dr. Hsu discuss why sustained delivery with the port delivery system may outperform even closely monitored intermittent injections.
